PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING SUBMISSION OR TRANSMITTAL OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

To:

SMITH, Elizabeth, Jane
The Boots Company plc
Group Patents Dept.
Building D31, 1 Thane Road West
Nottingham, Nottinghamshire NG2 3AA
ROYAUME-UNI

Date of mailing (day/month/year) 06 February 2001 (06.02.01)	
Applicant's or agent's file reference P/663	**IMPORTANT NOTIFICATION**
International application No. PCT/EP99/05753	International filing date (day/month/year) 04 August 1999 (04.08.99)
International publication date (day/month/year) 17 February 2000 (17.02.00)	Priority date (day/month/year) 05 August 1998 (05.08.98)
Applicant THE BOOTS COMPANY PLC et al	

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt, or by the letters "NR", in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).

2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.

3. An **asterisk(*)** appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

4. The **letters "NR"** appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, **the attention of the applicant is directed** to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
05 Augu 1998 (05.08.98)	9816899.0	GB	03 Nove 1999 (03.11.99)

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No. (41-22) 740.14.35

Authorized officer
Wagner

Telephone No. (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION OF ELECTION

(PCT Rule 61.2)

To:

Assistant Commissioner for Patents
United States Patent and Trademark Office
Box PCT
Washington, D.C.20231
ETATS-UNIS D'AMERIQUE

in its capacity as elected Office

Date of mailing (day/month/year) 17 April 2000 (17:04.00)	
International application No. PCT/EP99/05753	**Applicant's or agent's file reference** P/663
International filing date (day/month/year) 04 August 1999 (04.08.99)	**Priority date** (day/month/year) 05 August 1998 (05.08.98)
Applicant DICKINSON, Jeffrey et al	

1. The designated Office is hereby notified of its election made:

[X] in the demand filed with the International Preliminary Examining Authority on:
03 February 2000 (03.02.00)

[ ] in a notice effecting later election filed with the International Bureau on:

2. The election [X] was
[ ] was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer
Claudio Borton

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

From the INTERNATIONAL BUREAU

PCT

NOTIFICATION CONCERNING DOCUMENT TRANSMITTED

To:

Commissioner
US Department of Commerce
United States Patent and Trademark Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202
ETATS-UNIS D'AMERIQUE

in its capacity as designated Office

Date of mailing (day/month/year)	
06 February 2001 (06.02.01)	
International application No. PCT/EP99/05753	**International filing date** (day/month/year) 04 August 1999 (04.08.99)
Applicant THE BOOTS COMPANY PLC et al	

The International Bureau transmits herewith the following documents and number thereof:

_____ cop(ies) of priority document(s) (Rule 17.2(a))

The International Bureau of WIPO
34, chemin des Colombettes
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

N. Wagner

Telephone No.: (41-22) 338.83.38

PATENT COOPERATION TREATY

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
P/663		
International application No.	International filing date *(day/month/year)*	Priority date *(day/month/year)*
PCT/EP99/05753	04/08/1999	05/08/1998
International Patent Classification (IPC) or national classification and IPC A61K9/20		
Applicant THE BOOTS COMPANY PLC. et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.

2. This REPORT consists of a total of 7 sheets, including this cover sheet.

   ☒ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

   These annexes consist of a total of 2 sheets.

3. This report contains indications relating to the following items:

   - I ☒ Basis of the report
   - II ☒ Priority
   - III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
   - IV ☐ Lack of unity of invention
   - V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations suporting such statement
   - VI ☐ Certain documents cited
   - VII ☐ Certain defects in the international application
   - VIII ☒ Certain observations on the international application

Date of submission of the demand	Date of completion of this report
03/02/2000	13.10.2000
Name and mailing address of the international preliminary examining authority: European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer Smeets, D Telephone No. +49 89 2399

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP99/05753

I. Basis of th r port

1. This report has been drawn on the basis of (*substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.*):

D scription, pages:

1-9,11,13-31	as originally filed			
10,12	as received on	14/08/2000	with letter of	10/08/2000

Claims, No.:

1-24	as originally filed

2. The amendments have resulted in the cancellation of:

☐ the description, pages:
☐ the claims, Nos.:
☐ the drawings, sheets:

3. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

4. Additional observations, if necessary:

II. Priority

1. ☐ This report has been established as if no priority had been claimed due to the failure to furnish within the prescribed time limit the requested:

   ☐ copy of the earlier application whose priority has been claimed.

   ☐ translation of the earlier application whose priority has been claimed.

2. ☒ This report has been established as if no priority had been claimed due to the fact that the priority claim has been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

s e separate sheet

III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

☐ the entire international application.

☒ claims Nos. 24 concerning industrial applicability.

because:

☒ the said international application, or the said claims Nos. 24 relate to the following subject matter which does not require an international preliminary examination (*specify*):

see separate sheet

☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):

☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.

☐ no international search report has been established for the said claims Nos. .

V. R asoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)	Yes:	Claims	2, 6-7, 10-12, 16
	No:	Claims	1, 3-5, 8-9, 13-15, 17-24
Inventive step (IS)	Yes:	Claims	2
	No:	Claims	1, 3-24
Industrial applicability (IA)	Yes:	Claims	1-23
	No:	Claims	

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

Re Item II

Priority

The priority document (priority date: 05/08/1998) discloses that the examples of PCT/EP98/00649 are excluded from the scope of the present patent application. The claimed priority of the present application is not valid for the subject-matter of claims 1, 3, 8, 15 and 16 and any claim dependant on one of these claims, since the subject-matter of said claims does not exclude the examples of PCT/EP98/00649.
Consequently, D3 is considered to be comprised in the state of the art for the subject-matter of said claims.

Re Item III

Non-establishment of opinion with regard to novelty, inventive step and industrial applicability

Claim 24 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Article 34(4)(a)(i) PCT).

Re Item V

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

Reference is made to the following documents:

D1: CA-A-2 020 018 (SIMMONS DON L) 28 December 1991 (1991-12-28) cited in the application
D2: GB-A-2 313 309 (ON NINH) 26 November 1997 (1997-11-26) cited in the application
D3: WO 98 34612 A (PANKHANIA MAHENDRA GOVIND ;BOOTS CO PLC (GB); YURDAKUL SARUHAN (GB) 13 August 1998 (1998-08-13) cited in the application

1) Remarks concerning claim 24 with regard to industrial applicability

For the assessment of the present claim 24 on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

2) Novelty and Inventive Step - Art. 33(1), (2) and (3) PCT

D3 belongs to the state of the art for the subject-matter of independent claims 1, 3, 8, 15, 16 and any claim dependant on these claims.
The subject-matter of claim 1 lacks novelty in the light of D3 since examples 6-11 and 15-16 of said document fall within the scope of claim 1 of the present application.
The subject-matter of claims 3-5, 8, 9, 13-15, 17-24 is also not new in view of D3 (examples 6-11, 15-16).

Dependent claims 6, 7, 10-12 and independant claim 16 appear to relate to minor constructional features, which insofar as not directly disclosed in the prior art revealed in the present application and the search report, appear to relate to obvious modifications thereof. Therefore, the subject-matter of said claims does not meet the requirements set forth in Article 33 PCT.

The priority is validly claimed for the subject-matter of claim 2. Thus, D3 does not belong to the state of the art for the subject-matter of said claim.
D1 is being regarded as closest prior art for the subject-matter of claim 2.
The technical problem of this invention is a carrier system which provides alternative, stabilised formulations of ibuprofen and domperidone.
The present invention solves this problem by applying a carrier material to a pharmaceutical composition comprising ibuprofen and domperidone, substantially free of povidone, comprising at least one diluent combined with at least one release modifying agent.

D1 (claim 2 and 3) discloses a composition comprising an analgesic (see list on page 11, line 9 comprising ibuprofen) and an antinauseant (see list on page 11, line 12 comprising domperidone) and the following additional ingredients: glidants, lubricants, disintegrating agents, fillers and pigmenting materials.
In this connection a disintegrating agent is considered as a release modifying agent and a filler is considered as a diluent.
The subject-matter of claim 2 consists of the selection of a particular analgesic (ibuprofen) together with a particular antinauseant (domperidone) described in document 1.
In difference to D1, the present application (p.4, lines 4-16) teaches that povidone affects the stability of compositions containing both ibuprofen and domperidone and was therefor excluded from the claimed composition. D1 is silent as to that stability problem.
In D2 (p.4, line 32), povidone is disclosed as a suitable binder for a composition comprising domperidone and an analgesic. According to a list (D2, page 5, line 10) ibuprofen could be such an analgesic. In D2 however no suggestion is disclosed that povidone can affect the stability of such a composition and should be left out in compositions comprising ibuprofen and domperidone.
Hence, the subject-matter of claim 2 involves an inventive step since a composition comprising ibuprofen and domperidone but omitting povidone was not obvious in view of D1 and D2.

Re Item VIII

Certain observations on the international application

a) Although claims 2, 3, 8, 15 and 16 have been drafted as separate independent claims, they appear to relate effectively to the same subject-matter and to differ from each other only with regard to the definition of the subject-matter for which protection is sought and in respect of the terminology used for the features of that subject-matter. The aforementioned claims therefore lack conciseness. Moreover, lack of clarity of the claims as a whole arises, since the plurality of independent claims makes it difficult to determine the matter for which protection is sought, and places an undue burden on others seeking to establish the extent of the protection.
Hence, claims 2, 3, 8, 15 and 16 do not meet the requirements of Article 6 PCT.

compositions are administered in divided doses throughout the day so the amount of ibuprofen (or the corresponding amount of a salt thereof) to be administered at each dosing time is in the range 50 to 800mg (preferably 50 to 400mg, more preferably 200 to 400mg). Therefore, if two dosage forms are to be administered at each time, the dosage forms should contain 25 to 400mg (preferably 50 to 300mg, more preferably 100 to 200mg) ibuprofen medicament.

The domperidone medicament may be in the form of domperidone or a pharmaceutically acceptable salt thereof, particularly acid addition salts such as the maleate. Preferably, the domperidone medicament is in the form of domperidone or the maleate salt.

Representative compositions according to the present invention may comprise the domperidone medicament in an amount 0.1-20% by weight, suitably 0.5-15%, preferably 1-10% and more preferably 1-5% by weight of the composition. Unit dosages may comprise the domperidone medicament to an extent of 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 40mg and 50mg. Suitably the pharmaceutical compositions are administered in divided doses throughout the day so the amount of domperidone (or the corresponding amount of a salt thereof) to be administered at each dosing time is 5 to 50mg (preferably 5 to 25mg, more preferably 5 to 20mg). Therefore, if two dosage forms are to be administered at each time, the dosage forms should contain 2.5 to 25mg, (preferably 2.5 to 12.5mg, more preferably 2.5 to 10mg) domperidone medicament.

Preferred compositions according to the present invention are in the form of a unit dose comprising 50-400 mg ibuprofen medicament and 5-20 mg domperidone medicament. More preferred compositions comprise 100-400 mg or 100-200 mg ibuprofen medicament and 5-10 mg domperidone medicament.

The solid dosage form may be in the form of a controlled release tablet, a suppository, effervescent granules, a chewable table and a dissolving buccal dosage form or any other appropriate form. Preferably, the ibuprofen and domperidone medicaments are administered as a compressed solid dosage form, further preferably

the carrier.

The carrier consists of non-povidone containing ingredients. The carrier material comprises at least one inert diluent material, for example one or more of sugar diluents, salts and oxides of alkaline earth metals, cellulose diluents, methacrylate diluents, starch diluents, glyceryl and vegetable oil diluents. Examples of inert diluent materials include one or more of a sugar material, including sugar alcohols, (eg dextrose, lactose, sucrose, compressible sugar, mannitol and sorbitol), dextrates, dextrin, maltodextrin, calcium carbonate, calcium sulphate, dicalcium phosphate, tricalcium phosphate, glyceryl palmitostearate, hydrogenated vegetable oil (type I), kaolin, magnesium carbonate, magnesium oxide, microcrystalline cellulose, polymethacrylates, potassium chloride, powdered cellulose, hydroxypropylmethyl cellulose, pregelatinised starch, sodium chloride, starches (eg wheat starch, maize starch, potato starch, rice starch, tapioca starch) and modified starches. Preferred diluents have good cohesive properties and serve to bind the materials together. Further preferred diluents are compressible and include a cellulose component, a phosphate component, a starch component or a sugar component or mixtures thereof. Preferred examples of such diluents are microcrystalline cellulose, hydroxypropylmethyl cellulose, dicalcium phosphate, tricalcium phosphate, maltodextrin and soluble sugars such as lactose, sucrose and dextrin, especially microcrystalline cellulose, tricalcium phosphate and lactose. In an especially preferred composition, the carrier material consists essentially of one or more of the following diluents: microcrystalline cellulose, tricalcium phosphate and lactose. The most preferred diluents have a combination of good cohesion (or binding) and good compressibility. These properties may be provided by more than one excipient. These ingredients will be used in the composition in an amount as used by the person skilled in the art. This will generally be in the range 10-50% by weight of the composition, preferably 20-50% of the composition, more preferably 20-45% and most preferably 20-35% by weight of the composition.

Some inert diluents also have disintegrating properties, for example microcrystalline cellulose and/or hydroxypropylmethyl cellulose and therefore a discrete disintegrant material is not always necessary as the

compositions are administered in divided doses throughout the day so the amount of ibuprofen (or the corresponding amount of a salt thereof) to be administered at each dosing time is in the range 50 to 800mg (preferably 50 to 400mg, more preferably 200 to 400mg). Therefore, if two dosage forms are to be administered at each time, the dosage forms should contain 25 to 400mg (preferably 50 to 300mg, more preferably 100 to 200mg) ibuprofen medicament.

The domperidone medicament may be in the form of domperidone or a pharmaceutically acceptable salt thereof, particularly acid addition salts such as the maleate. Preferably, the domperidone medicament is in the form of domperidone or the maleate salt.

Representative compositions according to the present invention may comprise the domperidone medicament in an amount 0.1-20% by weight, suitably 0.5-15%, preferably 1-10% and more preferably 1-5% by weight of the composition. Unit dosages may comprise the domperidone medicament to an extent of 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 40mg and 50mg. Suitably the pharmaceutical compositions are administered in divided doses throughout the day so the amount of domperidone (or the corresponding amount of a salt thereof) to be administered at each dosing time is 5 to 50mg (preferably 5 to 25mg, more preferably 5 to 20mg). Therefore, if two dosage forms are to be administered at each time, the dosage forms should contain 2.5 to 25mg, (preferably 2.5 to 12.5mg, more preferably 2.5 to 10mg) domperidone medicament.

Preferred compositions according to the present invention are in the form of a unit dose comprising 100-400 mg or 100-200 mg ibuprofen medicament and 5-10 mg domperidone medicament.

The solid dosage form may be in the form of a controlled release tablet, a suppository, effervescent granules, a chewable table and a dissolving buccal dosage form or any other appropriate form. Preferably, the ibuprofen and domperidone medicaments are administered as a compressed solid dosage form, further preferably

the carrier.

The carrier consists of non-povidone containing ingredients. The carrier material comprises at least one inert diluent material, for example one or more of sugar diluents, salts and oxides of alkaline earth metals, cellulose diluents, methacrylate diluents, starch diluents, glyceryl and vegetable oil diluents. Examples of inert diluent materials include one or more of a sugar material, including sugar alcohols, (eg dextrose, lactose, sucrose, compressible sugar, mannitol and sorbitol), dextrates, dextrin, maltodextrin, calcium carbonate, calcium sulphate, dicalcium phosphate, tricalcium phosphate, glyceryl palmitostearate, hydrogenated vegetable oil (type I), kaolin, magnesium carbonate, magnesium oxide, microcrystalline cellulose, polymethacrylates, potassium chloride, powdered cellulose, hydroxypropylmethyl cellulose, pregelatinised starch, sodium chloride, starches (eg wheat starch, maize starch, potato starch, rice starch, tapioca starch) and modified starches. Preferred diluents have good cohesive properties and serve to bind the materials together. Further preferred diluents are compressible and include a cellulose component, a phosphate component, a starch component or a sugar component or mixtures thereof. Preferred examples of such diluents are microcrystalline cellulose, hydroxypropylmethyl cellulose, dicalcium phosphate, tricalcium phosphate, maltodextrin and soluble sugars such as lactose, sucrose and dextrin, especially microcrystalline cellulose, tricalcium phosphate and lactose. The most preferred diluents have a combination of good cohesion (or binding) and good compressibility. These properties may be provided by more than one excipient. These ingredients will be used in the composition in an amount as used by the person skilled in the art. This will generally be in the range 10-50% by weight of the composition, preferably 20-50% of the composition, more preferably 20-45% and most preferably 20-35% by weight of the composition.

Some inert diluents also have disintegrating properties, for example microcrystalline cellulose and/or hydroxypropylmethyl cellulose and therefore a discrete disintegrant material is not always necessary as the

PCT REQUEST

P/663

Original (for **SUBMISSION**) - printed on 03.08.1999 01:47:04 PM

0 0-1	**For receiving Office use only** International Application No.	PCT/EP 99 / 05753
0-2	International Filing Date	04 AUG 1999 (04.08.1999)
0-3	Name of receiving Office and "PCT International Application"	EUROPEAN PATENT OFFICE PCT INTERNATIONAL APPLICATION
0-4 0-4-1	**Form - PCT/RO/101 PCT Request** Prepared using	PCT-EASY Version 2.84 (updated 01.07.1999)
0-5	**Petition** The undersigned requests that the present international application be processed according to the Patent Cooperation Treaty	
0-6	**Receiving Office (specified by the applicant)**	European Patent Office (EPO) (RO/EP)
0-7	**Applicant's or agent's file reference**	P/663
I	**Title of invention**	THERAPEUTIC AGENTS
II II-1 II-2 II-4 II-5 II-6 II-7	**Applicant** This person is: Applicant for Name Address: State of nationality State of residence	applicant only all designated States except US THE BOOTS COMPANY PLC 1 THANE ROAD WEST NOTTINGHAM, Nottinghamshire NG2 3AA United Kingdom GB GB
III-1 III-1-1 III-1-2 III-1-4 III-1-5 III-1-6 III-1-7	**Applicant and/or inventor** This person is: Applicant for Name (LAST, First) Address: State of nationality State of residence	applicant and inventor US only DICKINSON, JEFFREY THE BOOTS COMPANY PLC 1 THANE ROAD WEST NOTTINGHAM, Nottinghamshire NG2 3AA United Kingdom GB GB

PCT REQUEST P/663

Original (for **SUBMISSION**) - printed on 03.08.1999 01:47:04 PM

III-2	**Applicant and/or inventor**	
III-2-1	This person is:	applicant and inventor
III-2-2	Applicant for	US only
III-2-4	Name (LAST, First)	MAKWANA, JAYANTILAL, VITHAL
III-2-5	Address:	THE BOOTS COMPANY PLC 1 THANE ROAD WEST NOTTINGHAM, Nottinghamshire NG2 3AA United Kingdom
III-2-6	State of nationality	GB
III-2-7	State of residence	GB
IV-1	**Agent or common representative; or address for correspondence** The person identified below is hereby/has been appointed to act on behalf of the applicant(s) before the competent International Authorities as:	agent
IV-1-1	Name (LAST, First)	SMITH, ELIZABETH, JANE
IV-1-2	Address:	GROUP PATENTS DEPT BUILDING D31 THE BOOTS COMPANY PLC 1 THANE ROAD WEST NOTTINGHAM, Nottinghamshire NG2 3AA United Kingdom
IV-1-3	Telephone No.	+44 115-959-4585
IV-1-4	Facsimile No.	+44 115-959-4599
IV-1-5	e-mail	elizabeth.smith@boots-plc.com
V	**Designation of States**	
V-1	Regional Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AP: GH GM KE LS MW SD SL SZ UG ZW and any other State which is a Contracting State of the Harare Protocol and of the PCT EA: AM AZ BY KG KZ MD RU TJ TM and any other State which is a Contracting State of the Eurasian Patent Convention and of the PCT EP: AT BE CH&LI CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE and any other State which is a Contracting State of the European Patent Convention and of the PCT OA: BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG and any other State which is a member State of OAPI and a Contracting State of the PCT
V-2	National Patent (other kinds of protection or treatment, if any, are specified between parentheses after the designation(s) concerned)	AE AL AM AT AU AZ BA BB BG BR BY CA CH&LI CN CR CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

PCT REQUEST P/663

Original (for **SUBMISSION**) - printed on 03.08.1999 01:47:04 PM

V-5	**Pr cautionary Designation Statement** In addition to th designations made under items V-1, V-2 and V-3, th applicant also makes under Rule 4.9(b) all designations which would be permitted under the PCT except any designation(s) of the State(s) indicated under item V-6 below. The applicant declares that those additional designations are subject to confirmation and that any designation which is not confirmed before the expiration of 15 months from the priority date is to be regarded as withdrawn by the applicant at the expiration of that time limit.		
V-6	**Exclusion(s) from precautionary designations**	NONE	
VI-1	**Priority claim of earlier national application**		
VI-1-1	Filing date	05 August 1998 (05.08.1998)	
VI-1-2	Number	9816899.0	
VI-1-3	Country	GB	
VII-1	**International Searching Authority Chosen**	European Patent Office (EPO) (ISA/EP)	
VIII	**Check list**	number of sheets	electronic file(s) attached
VIII-1	Request	4	-
VIII-2	Description	31	-
VIII-3	Claims	5	-
VIII-4	Abstract	1	663abstr.txt
VIII-5	Drawings	0	-
VIII-7	TOTAL	41	
	Accompanying Items	paper document(s) attached	electronic file(s) attached
VIII-8	Fee calculation sheet	✓	-
VIII-12	Priority document(s)	Item(s) VI-1	-
VIII-16	PCT-EASY diskette	-	diskette
VIII-18	**Figure of the drawings which should accompany the abstract**		
VIII-19	**Language of filing of the international application**	English	
IX-1	**Signature of applicant or agent**	E.J Smith	
IX-1-1	Name (LAST, First)	SMITH, ELIZABETH, JANE	

FOR RECEIVING OFFICE USE ONLY

10-1	**Date of actual receipt of the purported international application**	04 AUG 1999	04 08 1999
10-2	**Drawings:**		
10-2-1	Received		
10-2-2	Not received		
10-3	**Corrected date of actual receipt due to later but timely r ceived papers or drawings completing the purported international application**		
10-4	**Date of timely rec ipt of the required corrections under PCT Article 11(2)**		
10-5	**International Searching Authority**	ISA/EP	

10-6	Transmittal of search copy delayed until s arch fe is paid	

FOR INTERNATIONAL BUREAU USE ONLY

11-1	Date of receipt of the record copy by the International Bureau	

PATENT COOPERATION TREATY

PCT

INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference	**FOR FURTHER ACTION** see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.	
P/663		
International application No.	International filing date *(day/month/year)*	(Earliest) Priority Date *(day/month/year)*
PCT/EP 99/ 05753	04/08/1999	05/08/1998

Applicant

THE BOOTS COMPANY PLC. et al.

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 3 sheets.

[X] It is also accompanied by a copy of each prior art document cited in this report.

1. **Basis of the report**

   a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

   [ ] the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

   b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

   [ ] contained in the international application in written form.

   [ ] filed together with the international application in computer readable form.

   [ ] furnished subsequently to this Authority in written form.

   [ ] furnished subsequently to this Authority in computer readble form.

   [ ] the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

   [ ] the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. [X] **Certain claims were found unsearchable** (See Box I).

3. [ ] **Unity of invention is lacking** (see Box II).

4. With regard to the **title,**

   [ ] the text is approved as submitted by the applicant.

   [X] the text has been established by this Authority to read as follows:

   PHARMACEUTICAL COMPOSITIONS COMPRISING IBUPROFEN AND DOMPERIDONE

5. With regard to the **abstract,**

   [X] the text is approved as submitted by the applicant.

   [ ] the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No. --

   [ ] as suggested by the applicant.

   [ ] because the applicant failed to suggest a figure.

   [ ] because this figure better characterizes the invention.

   [ ] None of the figures.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 99/05753

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim 24 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/05753

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/20 A61K31/445 //(A61K31/445,31:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CA 2 020 018 A (SIMMONS DON L) 28 December 1991 (1991-12-28) cited in the application claims 1-3,7,8; examples	1-5, 8-13,15, 17-21,24
X	GB 2 313 309 A (ON NINH) 26 November 1997 (1997-11-26) cited in the application page 4, line 13 - line 36; claims	1-3,5,6, 8,10-12, 15,16, 19-21,24
P,X	WO 98 34612 A (PANKHANIA MAHENDRA GOVIND ;BOOTS CO PLC (GB); YURDAKUL SARUHAN (GB)) 13 August 1998 (1998-08-13) cited in the application page 2, line 14 -page 7, line 11 claim 1; examples 6-11,15,16	1-24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 January 2000	27/01/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Epskamp, S

Form PCT/ISA/210 (second sheet) (July 1992)

IN NATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 99/05753

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CA 2020018 A	28-12-1991	US 5273759 A	28-12-1993
GB 2313309 A	26-11-1997	NONE	
WO 9834612 A	13-08-1998	AU 6295598 A	26-08-1998
		CZ 9902709 A	13-10-1999
		GB 2331926 A	09-06-1999
		NO 993784 A	22-09-1999
		ZA 9800968 A	06-08-1998

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 :
A61K 9/20, 31/445 // (A61K 31/445, 31:19)

A1

(11) International Publication Number: WO 00/07570

(43) International Publication Date: 17 February 2000 (17.02.00)

(21) International Application Number: PCT/EP99/05753

(22) International Filing Date: 4 August 1999 (04.08.99)

(30) Priority Data:
9816899.0 5 August 1998 (05.08.98) GB

(71) Applicant *(for all designated States except US)*: THE BOOTS COMPANY PLC [GB/GB]; 1 Thane Road West, Nottingham, Nottinghamshire NG2 3AA (GB).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: DICKINSON, Jeffrey [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham, Nottinghamshire NG2 3AA (GB). MAKWANA, Jayantilal, Vithal [GB/GB]; The Boots Company plc, 1 Thane Road West, Nottingham, Nottinghamshire NG2 3AA (GB).

(74) Agent: SMITH, Elizabeth, Jane; The Boots Company plc, Group Patents Dept., Building D31, 1 Thane Road West, Nottingham, Nottinghamshire NG2 3AA (GB).

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING IBUPROFEN AND DOMPERIDONE

(57) Abstract

A stable pharmaceutical composition comprising a mixture of (i) an ibuprofen medicament; (ii) a domperidone medicamement; and (iii) a carrier material characterized in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	**ES**	Spain	**LS**	Lesotho	**SI**	Slovenia
AM	Armenia	**FI**	Finland	**LT**	Lithuania	**SK**	Slovakia
AT	Austria	**FR**	France	**LU**	Luxembourg	**SN**	Senegal
AU	Australia	**GA**	Gabon	**LV**	Latvia	**SZ**	Swaziland
AZ	Azerbaijan	**GB**	United Kingdom	**MC**	Monaco	**TD**	Chad
BA	Bosnia and Herzegovina	**GE**	Georgia	**MD**	Republic of Moldova	**TG**	Togo
BB	Barbados	**GH**	Ghana	**MG**	Madagascar	**TJ**	Tajikistan
BE	Belgium	**GN**	Guinea	**MK**	The former Yugoslav Republic of Macedonia	**TM**	Turkmenistan
BF	Burkina Faso	**GR**	Greece			**TR**	Turkey
BG	Bulgaria	**HU**	Hungary	**ML**	Mali	**TT**	Trinidad and Tobago
BJ	Benin	**IE**	Ireland	**MN**	Mongolia	**UA**	Ukraine
BR	Brazil	**IL**	Israel	**MR**	Mauritania	**UG**	Uganda
BY	Belarus	**IS**	Iceland	**MW**	Malawi	**US**	United States of America
CA	Canada	**IT**	Italy	**MX**	Mexico	**UZ**	Uzbekistan
CF	Central African Republic	**JP**	Japan	**NE**	Niger	**VN**	Viet Nam
CG	Congo	**KE**	Kenya	**NL**	Netherlands	**YU**	Yugoslavia
CH	Switzerland	**KG**	Kyrgyzstan	**NO**	Norway	**ZW**	Zimbabwe
CI	Côte d'Ivoire	**KP**	Democratic People's Republic of Korea	**NZ**	New Zealand		
CM	Cameroon			**PL**	Poland		
CN	China	**KR**	Republic of Korea	**PT**	Portugal		
CU	Cuba	**KZ**	Kazakstan	**RO**	Romania		
CZ	Czech Republic	**LC**	Saint Lucia	**RU**	Russian Federation		
DE	Germany	**LI**	Liechtenstein	**SD**	Sudan		
DK	Denmark	**LK**	Sri Lanka	**SE**	Sweden		
EE	Estonia	**LR**	Liberia	**SG**	Singapore		

PHARMACEUTICAL COMPOSITIONS COMPRISING IBUPROFEN AND DOMPERIDONE

This invention relates to pharmaceutical compositions comprising an ibuprofen medicament and a domperidone medicament.

Ibuprofen, namely 2-(4-isobutylphenyl)propionic acid, is a well known medicament with analgesic, anti-inflammatory and anti-pyretic properties. It is usually sold in the form of racemic ibuprofen (equal amounts of the S(+)-ibuprofen and R(-)-ibuprofen enantiomers). It may also be in the form of the purified form of either enantiomer, especially S(+)-ibuprofen which is acknowledged to be the active form of racemic ibuprofen. Ibuprofen is also available in salt form, for example the sodium or lysine salt of ibuprofen. Ibuprofen is available under prescription (eg Brufen (RTM)), primarily for the treatment of painful and anti-inflammatory disorders including rheumatoid arthritis, ankylosing spondylitis, osteoarthritis, postoperative pain, post partum pain and soft tissue injuries, generally at doses up to 3200 mg per day. Ibuprofen is also available as a non-prescription drug (eg Nurofen (RTM)), primarily for the treatment of symptoms of pain and fever including headache, migraine, rheumatic pain, muscular pain, backache, neuralgia, dysmenorrhoea, dental pain and colds and flu, generally at doses up to 1200mg per day. The commercially available ibuprofen tablets usually contain ibuprofen or an enantiomer or salt thereof equivalent to 200mg, 400 mg, 600 mg or 800 mg racemic ibuprofen. Hereinafter the term "ibuprofen" means any enantiomer of ibuprofen or mixtures of enantiomers including the racemic mixture.

Domperidone, namely 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl-4-piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one is a well known medicament with antiemetic properties. Domperidone is available under prescription [eg Motilium (RTM)] as tablets for the treatment of functional dyspepsia at doses of up to 80 mg per day and is also available as tablets, suspensions or suppositories for the treatment of emesis (in nausea or vomiting) at doses of up to 120 mg per day. Pharmaceutically acceptable salts, eg the maleate salt of domperidone may be used instead of domperidone itself. In this

case the amount of active material is adjusted so as to administer an equivalent amount of domperidone base.

Administration of analgesic NSAIDs (such as ibuprofen) together with domperidone has been proposed for use in the treatment of migraine, see for example GB 2313309 and CA 2020018. When two actives are administered as a combined treatment, it is advantageous to provide them together in the same dosage form rather than administer them sequentially in different dosage forms. A generalised discussion of typical formulation excipients useful to provide unit dosage forms is provided in the references noted above but no compositions of ibuprofen and domperidone are specifically illustrated in these patent applications.

A problem has arisen however, that when it is desired to administer the ibuprofen and domperidone active ingredients in the same pharmaceutical formulation, it has been found that solid formulations may not be stable on storage.

In formulating solid dosage forms of active ingredients, a wide variety of excipients may be employed. These may be selected to provide a formulation that is sufficiently robust that it can withstand production, transportation and storage procedures. However, it is also important to ensure that the composition releases the active ingredients at an appropriate rate in the body following administration to the patient to allow each active ingredient to be provided in a precisely determined amount and to have the desired release profile to suit the therapeutic treatment for which it is administered. Thus, ingredients must be chosen which meet both requirements. Excipients which have cohesive properties to bind the combination of ingredients are important in formulating solid compositions. Further useful excipients are release modifying agents, such as disintegrating agents for conventional immediate release tablets and sustained release carriers where it is desired to release the medicaments over a longer period. When the dosage form is exposed to the aqueous medium after ingestion, these release modifying excipients cause the solid composition to release the

active ingredient at a desired rate, for example substantially immediately or at a desired controlled rate. There may also be provided carrier materials which allow the homogeneous mixing of the active ingredients throughout the dosage form and which may aid compressibility of the tablets. Such carrier materials may have disintegrating properties and/or cohesive properties when used in certain proportions in the dosage form. Other excipients may also be added as necessary for particular drugs to provide appropriate release and absorption into the body.

In the production of solid dosage forms there is often a granulation stage in which the active ingredient is combined with an inert excipient and formed into a free-flowing, homogeneous granular composition which is capable of being mixed with other ingredients and formed into a solid dosage form. In this granulation stage, most commonly the powdered ingredients are mixed and then granulated with a granulating fluid (eg water or a pharmaceutically acceptable organic solvent such as an alcoholic solvent) to form a granular composition. A granulating agent which may be a solid and which further imparts cohesive properties to the granule may be present, either dissolved in the granulating liquid or mixed in with the powdered ingredients. Povidone is a preferred granulating agent as it is readily soluble both in water and in alcoholic solvents and it provides good cohesive properties to the resulting granule. Povidone has been used previously in providing both granular compositions of ibuprofen and granular compositions of domperidone. Povidone is of particular value in the manufacturing process because it allows changes in the composition of the granulating fluid (eg water may replace the alcoholic solvent or the water and alcohol may be combined in a desired proportion) without affecting the solid ingredients in the composition. Such changes in the granulating fluid may be necessary to optimise the quality of the granular product to ensure a desired solid composition is produced during the production scaling up process between lab scale and a full production batch. It is also of advantage to use povidone in the composition because its ready solubility contributes to the disintegration of the solid dosage form when in the gastro-intestinal tract. Thus, povidone is acknowledged to be a

preferred material, especially as granulating agent in compositions containing ibuprofen and is very widely used.

However, it has been found that compositions containing ibuprofen, domperidone and povidone are unstable on storage, for example leading to a reduction in the amount of active ingredient available for absorption, particularly domperidone.

This is a very significant finding for the above combination of active ingredients because povidone is such a widely used pharmaceutical excipient, particularly in the production of tablets. As well as affecting compositions containing granulated ibuprofen together with domperidone, the presence of povidone will also affect other solid formulations containing this combination of active ingredients and also any other composition wherein the ibuprofen, domperidone and povidone are combined, for example liquids and semi-solids.

Thus, in accordance with the invention we have now found a carrier system which provides stabilised formulations of ibuprofen and domperidone.

According to the invention there is provided a stable pharmaceutical composition comprising a mixture of:-

(i) an ibuprofen medicament;
(ii) a domperidone medicament; and
(iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent.

WO 98/34612 was published 13 August 1998. The disclosure relates to a combined drug treatment of an ibuprofen medicament with a domperidone medicament. Pharmaceutical compositions containing the two active ingredients suitable for administration to patients are

discussed therein, including solid compositions for oral administration, liquid fill compositions and oral liquid compositions, compositions for topical administration, rectal administration and parenteral administration and also spray formulations. Some solid compositions are disclosed which may comprise a diluent, a lubricating agent, a disintegrating agent and optionally a binder and/or a flow aid. The preferred binder (which reflects the state of the art as given above) is said to be polyvinylpyrrolidone and this is reflected by its use as an excipient in a number of illustrative solid compositions. However, in the range of illustrative Examples provided, a number omit to use polyvinylpyrrolidone (see Examples 6 and 7 which granulate the ibuprofen and domperidone active ingredient with a carrier material consisting essentially of maize starch (at 35-38% of total tablet weight) and dried maize starch (at 3-4% of total tablet weight); Examples 8 and 9 disclose hard gelatin capsule compositions comprising a carrier consisting essentially of maize starch (at 15-20% by weight of total capsule contents) and pre-gelled starch (at 5-6% by weight of total capsule contents); Examples 9 and 10 also disclose tablets comprising granulated ibuprofen with a carrier consisting essentially of microcrystalline cellulose (at 10-11% total tablet weight) in combination with croscarmellose sodium (at 14-16% total tablet weight) and pre-gelled starch (at 10% of total tablet weight); Examples 15 and 16 directly compress all the ingredients, without a granulation stage, and comprise a carrier material consisting essentially of microcrystalline cellulose (at 8-11% total tablet weight) and lactose (at 5-6% of the total tablet weight).

However, there is no suggestion in WO 98/134612 of the advantages in stability to be obtained in a single dosage form comprising an ibuprofen medicament and a domperidone medicament by providing a carrier substantially free of polyvinylpyrrolidone. The compositions specifically disclosed in the above identified Examples of WO 98/34612 may be excluded from the scope of the present patent application where they constitute prior art. Such excluded subject matter can be considered to be:-

(a) a compressed tablet comprising granulated ibuprofen and a carrier material consisting essentially of either maize starch at 35-38% total tablet weight in combination with dried maize starch at 3-4% total tablet weight or microcrystalline cellulose at 10-11% total tablet weight in combination with croscarmellose sodium at 14-16% total tablet weight and pre-gelled starch at 10% total tablet weight;

(b) a direct compression tablet comprising a carrier material consisting essentially of microcrystalline cellulose at 8-11% total tablet weight and lactose at 5-6% total tablet weight;

(c) a hard gelatin capsule comprising a carrier consisting essentially of maize starch at 15-20% total capsule contents weight in combination with pre-gelled starch at 5-6% total capsule contents weight.

Povidone is the internationally accepted terminology for 1-Ethenyl-2-pyrrolidone homopolymer, also known as polyvinylpyrrolidone. Herein, the words 'povidone' and 'polyvinylpyrrolidone' are used interchangeably. Povidone is soluble in water. The term 'povidone' as used herein also includes 'crospovidone' which is a cross-linked homopolymer of N-vinyl-2-pyrrolidinone. The chemical name of crospovidone is 1-Ethenyl-2-pyrrolidinone homopolymer. Crospovidone is insoluble in water. It has been found that compositions comprising crospovidone are more unstable than compositions comprising povidone.

The dosage forms of the present form may be in solid, semi-solid or liquid form. In a preferred aspect, the present invention provides a compressed tablet composition including an ibuprofen medicament, a domperidone medicament and a carrier material comprising a compressed mixture of

(a) a granular component comprising said ibuprofen medicament and

at least a first portion of said carrier material; and

(b) a powder component comprising a lubricant material and an optional further portion of said carrier material,

said domperidone medicament being present in either of components (a) and (b), characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one disintegrating agent.

In a further preferred aspect, the present invention provides a directly compressed tablet composition comprising

(i) an ibuprofen medicament;
(ii) a domperidone medicament; and
(iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one disintegrating agent and a lubricating agent .

In a further preferred aspect, the present invention provides a solid composition comprising a non-compressed mixture of

(i) an ibuprofen medicament;
(ii) domperidone medicament; and
(iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent.

In a further preferred aspect, the present invention provides a liquid or semi-solid composition comprising

(i) an ibuprofen medicament;
(ii) a domperidone medicament; and

(iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent.

In a still further preferred aspect, the present invention provides a solid pharmaceutical composition comprising:

(a) an ibuprofen medicament;
(b) a domperidone medicament; and
(b) a carrier comprising a diluent combined with a disintegrating agent;

characterised in that the carrier is substantially free of water-soluble polyvinylpyrrolidone.

Where WO 98/34612 constitutes prior art, there may be excluded

(a) compositions wherein the carrier comprises a mixture of 15-38% by weight maize starch or 9-11% microcrystalline cellulose in combination with a starch component comprising 3-6% by weight dried maize starch or 6-10% by weight pre-gelled starch;

(b) tablets formed by direct compression containing 9-11% microcrystalline cellulose and 5-6% by weight lactose.

In a still further preferred aspect, the present invention provides a solid pharmaceutical composition formed by compressing a granular composition comprising:

(a) an ibuprofen medicament;
(b) a domperidone medicament; and
(c) a carrier comprising at least one diluent and at least one disintegrating agent said carrier being adapted to combine the ingredients in a stable composition;

optionally combined with other ingredients characterised in that the granular composition is formed by a granulation process in the absence of water-soluble polyvinylpyrrolidone.

The ibuprofen molecule exists in two enantiomeric forms and the term ibuprofen medicament as used herein is intended to embrace the individual enantiomers, especially S(+)-ibuprofen, and mixtures thereof in any proportion including a 1:1 mixture which is herein referred to as racemic ibuprofen. The ibuprofen medicament may be also present in the form of any salt or other derivative of ibuprofen or its enantiomers. If necessary, the ibuprofen medicament may comprise one or more ibuprofen active ingredients such as racemic ibuprofen and S(+)-ibuprofen in combination. However, we prefer that the ibuprofen medicament comprises a single ibuprofen active ingredient. Representative examples of salts of racemic or S(+)-ibuprofen include alkali metal salts, for example the sodium or potassium salts of ibuprofen; alkaline earth metal salts, eg the calcium or magnesium salts of ibuprofen; metal salts, eg the aluminium salt of ibuprofen; amino acid salts for example the lysine or arginine salts of ibuprofen; or amine salts, eg the meglumine salt of ibuprofen. Preferably the ibuprofen medicament is racemic ibuprofen, S(+)-ibuprofen or the sodium or lysine salt thereof, most preferably, racemic ibuprofen.

It is generally desired to have as high a proportion of ibuprofen medicament in the dosage form as possible to reduce the size of the solid dosage form. Representative dosage forms generally comprise ibuprofen medicament to an extent to give 35-90% by weight ibuprofen medicament by weight of the formulation, preferably 35-75% by weight, more preferably 40-70% by weight and most preferably 50-65% by weight. Unit dosages may comprise ibuprofen medicament to an extent of 50mg, 100mg, 150mg, 200mg, 250mg, 300mg, 350mg, 400mg, 500mg, 600mg and 800mg. Where salts or other derivatives are employed, usually the precise unit doses are chosen to give the equivalent ibuprofen doses set out above, for example 256mg of the sodium salt dihydrate or 342mg of the dl lysine salt provides an equivalent dose to 200mg ibuprofen. Suitably the pharmaceutical

compositions are administered in divided doses throughout the day so the amount of ibuprofen (or the corresponding amount of a salt thereof) to be administered at each dosing time is in the range 50 to 800mg (preferably 50 to 400mg, more preferably 200 to 400mg). Therefore, if two dosage forms are to be administered at each time, the dosage forms should contain 25 to 400mg (preferably 50 to 300mg, more preferably 100 to 200mg) ibuprofen medicament.

The domperidone medicament may be in the form of domperidone or a pharmaceutically acceptable salt thereof, particularly acid addition salts such as the maleate. Preferably, the domperidone medicament is in the form of domperidone or the maleate salt.

Representative compositions according to the present invention may comprise the domperidone medicament in an amount 0.1-20% by weight, suitably 0.5-15%, preferably 1-10% and more preferably 1-5% by weight of the composition. Unit dosages may comprise the domperidone medicament to an extent of 5mg, 10mg, 15mg, 20mg, 25mg, 30mg, 40mg and 50mg. Suitably the pharmaceutical compositions are administered in divided doses throughout the day so the amount of domperidone (or the corresponding amount of a salt thereof) to be administered at each dosing time is 5 to 50mg (preferably 5 to 25mg, more preferably 5 to 20mg). Therefore, if two dosage forms are to be administered at each time, the dosage forms should contain 2.5 to 25mg, (preferably 2.5 to 12.5mg, more preferably 2.5 to 10mg) domperidone medicament.

Preferred compositions according to the present invention are in the form of a unit dose comprising 100-400 mg or 100-200 mg ibuprofen medicament and 5-10 mg domperidone medicament.

The solid dosage form may be in the form of a controlled release tablet, a suppository, effervescent granules, a chewable table and a dissolving buccal dosage form or any other appropriate form. Preferably, the ibuprofen and domperidone medicaments are administered as a compressed solid dosage form, further preferably

orally.

Preferred solid dosage forms are in the form of orally administered tablets (conventional, sustained and mixed release profiles), gelatin capsules (hard and soft), dispersible tablets, chewable tablets, effervescent powders and granules. More preferably the solid dosage form is a tablet, either formed by direct compression of the powdered ingredients or by granulating the ibuprofen medicament, in which case the domperidone medicament may be in the granular component or in a powdery component combined with the granular component.

A unit dosage form preferably contains one or two dosage forms, preferably tablets.

The compositions according to the present invention may be adapted for substantially immediate release, for controlled release or there may be a different rate of release for each active ingredient. Thus, the composition may exhibit a range of release profiles. For example the period over which each drug is released may commence shortly after ingestion or, if the dosage form permits, a controlled release may commence after a time. The desired release profile is generally determined by a number of factors, including the nature of the active ingredient, the type of therapy and the nature of the excipient providing controlled release. The composition may optionally be provided with one or more layers which substantially prevent release until the dosage form reaches a certain point in the gastro-intestinal tract (eg determined by pH) or which acts as a barrier and thus reduces the rate of release. There may also be provided optional layers which may also contribute to the release profile of the active ingredients.

The carrier suitably forms up to 65% by weight of the dosage form. Preferred dosage forms include 20-60% by weight carrier, more preferably 25-60% by weight and most preferably 30-50%. The carrier is adapted to combine the components to form a stable solid composition. The ibuprofen and domperidone may thus be combined as a single unit dose, preferably as an intimate admixture together with

the carrier.

The carrier consists of non-povidone containing ingredients. The carrier material comprises at least one inert diluent material, for example one or more of sugar diluents, salts and oxides of alkaline earth metals, cellulose diluents, methacrylate diluents, starch diluents, glyceryl and vegetable oil diluents. Examples of inert diluent materials include one or more of a sugar material, including sugar alcohols, (eg dextrose, lactose, sucrose, compressible sugar, mannitol and sorbitol), dextrates, dextrin, maltodextrin, calcium carbonate, calcium sulphate, dicalcium phosphate, tricalcium phosphate, glyceryl palmitostearate, hydrogenated vegetable oil (type I), kaolin, magnesium carbonate, magnesium oxide, microcrystalline cellulose, polymethacrylates, potassium chloride, powdered cellulose, hydroxypropylmethyl cellulose, pregelatinised starch, sodium chloride, starches (eg wheat starch, maize starch, potato starch, rice starch, tapioca starch) and modified starches. Preferred diluents have good cohesive properties and serve to bind the materials together. Further preferred diluents are compressible and include a cellulose component, a phosphate component, a starch component or a sugar component or mixtures thereof. Preferred examples of such diluents are microcrystalline cellulose, hydroxypropylmethyl cellulose, dicalcium phosphate, tricalcium phosphate, maltodextrin and soluble sugars such as lactose, sucrose and dextrin, especially microcrystalline cellulose, tricalcium phosphate and lactose. The most preferred diluents have a combination of good cohesion (or binding) and good compressibility. These properties may be provided by more than one excipient. These ingredients will be used in the composition in an amount as used by the person skilled in the art. This will generally be in the range 10-50% by weight of the composition, preferably 20-50% of the composition, more preferably 20-45% and most preferably 20-35% by weight of the composition.

Some inert diluents also have disintegrating properties, for example microcrystalline cellulose and/or hydroxypropylmethyl cellulose and therefore a discrete disintegrant material is not always necessary as the

diluent material is thus combined with a disintegrating agent. However, in conventional or fast release tablets, we prefer to use a discrete disintegrating component in addition to the diluent, whether or not the diluent has disintegrating properties. Other diluents are substantially without disintegrating properties, eg some soluble diluents. This is within the knowledge of a person skilled in the art. Reference may also be made to the Handbook of Pharmaceutical Excipients (2nd Edition, Ed. Wade & Weller).

Examples of disintegrating agents include one or more of alginic acid, calcium carboxymethylcellulose, sodium carboxymethylcellulose, colloidal silicon dioxide, croscarmellose sodium, guar gum, magnesium aluminium silicate, methylcellulose, microcrystalline cellulose, powdered cellulose, starch (eg wheat starch, maize starch, potato starch, rice starch, tapioca starch), pregelatinised starch, sodium alginate, sodium starch glycolate, low-substituted hydroxypropyl cellulose or mixtures thereof. Preferably the composition according to the present invention includes at least one disintegrating agent. Preferred disintegrants comprise one or more of croscarmellose sodium and sodium starch glycolate. These ingredients will be used in the composition in an amount as used by the person skilled in the art. This will generally be in the range up to 15% by weight of the composition, for example 1-10% by weight, preferably 2-8% by weight of the dosage form.

The release modifying agent may also comprise agents which slow down the release of either medicament such as water-swellable polymers (eg cellulose ethers or gums such as xanthan gum and sodium alginate) or film forming polymers (eg ethyl cellulose or acrylic resin).

Preferred compositions comprise 20-60% by weight of carrier material including up to15% by weight of discrete disintegrant material. Further preferred compositions comprise a carrier material consisting essentially of a diluent substantially without disintegrating properties (for example tricalcium phosphate), a diluent with disintegrating

properties (for example microcrystalline cellulose), a discrete disintegrant (for example croscarmellose sodium) and a lubricating agent (for example magnesium stearate or stearic acid).

The composition may also include further ingredients. These ingredients will be used in the composition in an amount as used by the person skilled in the art. These may include a flow aid, such as talc or colloidal silicon dioxide which may preferably be used up to an extent of 4% by weight of the composition, for example 0.5-2.0% by weight of the composition. Lubricants such as stearic acid, sodium lauryl sulphate, polyethylene glycol, hydrogenated vegetable oil, hydrogenated cotton seed oil, calcium stearate, sodium stearyl fumarate or magnesium stearate or mixtures thereof may also be included in the composition. These may be used to an extent of up to 4% by weight of the dosage form, for example 0.5-2% by weight of the composition. Anti-adherents such as talc may further be included in an amount of up to 4% by weight of the composition. For example, 0.5-2% by weight of the composition.

Most commonly, the components will be compressed into tablets in a solid composition according to the present invention. Thus, the carrier is capable of being compressed with the active ingredients to form a robust tablet with cohesive properties. The tabletting process may contain a granulation stage in which at least one of the active ingredients and at least a portion of the diluent is mixed with a granulating fluid, either in the presence or absence of a granulating agent and formed into a granular composition which has sufficient free-flowing and cohesive properties to be capable of further processing with other excipients and compressed into a tablet. The granulation stage may also be carried out under dry conditions, ie in the absence of a granulating fluid.

Thus, in a preferred aspect of the present invention, there is provided a solid pharmaceutical composition comprising a compressed mixture of

(i) granules comprising the ibuprofen medicament and optionally the domperidone medicament, a carrier material including a release-modifying excipient; and

(ii) a lubricant and optionally a flow aid.

The composition may be formed by compressing the granular composition with the lubricant and optional flow aid together with other optional ingredients and is characterised in that the granular composition is formed by a granulation process in the absence of water-soluble polyvinyl pyrrolidone.

The granulation step may be carried out under dry conditions using techniques such as slugging or roller-compaction or by melt-extrusion. It is preferred to include a liquid in the granulation process. This is termed a "wet-granulation" process. In a preferred wet-granulation process, a granulating fluid is used in which the ibuprofen is soluble. Thus, the dissolved ibuprofen, on drying, contributes to the cohesiveness of the granular composition without requiring a granulating agent, such as water-soluble polyvinyl pyrrolidone to be employed in the granulation process. If desired, however, a granulating agent may be employed. A preferred granulating liquid is isopropyl alcohol. In another preferred process a granulating fluid is selected in which the ibuprofen may be substantially insoluble or only partially soluble (eg in water) and it may be of advantage to further include a granulating agent.

In a further preferred aspect of the invention, there is provided a solid pharmaceutical composition comprising as ingredients:-

(a) an ibuprofen medicament;
(b) a domperidone medicament;
(c) a carrier comprising a mixture of an inert diluent, a disintegrating component, at least one diluent having disintegrating properties and a granulating agent said carrier being adapted to combine the ingredients in a stable composition.

Thus, preferably the composition further comprises a granulating agent. The term "granulating agent" and "binding agent" herein are used interchangeably. A wet granulation process is particularly preferred, where the granulating agent imparts cohesive properties to the powdered materials. This may be achieved in the presence of a suitable solvent (preferably water) which causes the granulating agent to stick to the surrounding granular or powdery material and which on drying maintains the cohesion between the particles. Preferably the solid compositions according to the present invention are produced by a process including a wet granulation stage in the presence of a granulating fluid and a granulating agent. The granulating agent may be a solid; it may be present as a solid powder material or it may be dissolved in the granulating fluid. The granulating agent is preferably selected from a polymeric material, eg a natural or synthetic gum, or a cellulose material, a sugar granulating agent and a starch granulating agent. Examples of granulating agents or binders include, as polymeric materials, acacia, alginic acid, carbomer, carboxymethylcellulose sodium, alkyl celluloses (such as methylcellulose and ethylcellulose), gelatin, guar gum, hydroxyalkyl celluloses (such as hydroxyethylcellose, hydroxypropyl cellulose, hydroxypropylmethyl cellulose), polymethyacrylates, sodium alginate; as sugar granulating agents (including sugar alcohols), liquid glucose, maltodextrin, sucrose and sorbitol; as starch granulating agents, dextrin, pregelatinised starch, starch (eg wheat starch, maize starch, potato starch, rice starch, tapioca starch) and modified starch; and also magnesium aluminium silicate and zein; or mixtures thereof. Preferred polymer materials are hydroxypropyl cellulose and hydroxypropylmethyl cellulose. These ingredients will be used in the composition in an amount as used by the person skilled in the art. This will generally be in the range of up to 10% by weight (eg 0.1-10%), or preferably 0.5-5% by weight and most preferably 2-4%.

In a particularly preferred aspect of the present invention the pharmaceutical composition is in the form of a granulation, ie it is in granular form. In a further preferred aspect, the pharmaceutical composition is a solid dosage form, preferably a tablet.

A composition according to the present invention may be coated, eg with a sugar or film coating which has minimal effect on the disintegration time. A preferred solid dosage form of the present invention, ie a tablet, may be film or sugar coated by conventional coating techniques.

The compositions according to the present invention are formed by combining the ingredients, for example incorporating said ibuprofen medicament and said domperidone medicament with the carrier material as a homogeneous blend, and providing them in a suitable unit dosage form, eg by compression, by a spraying process or by filling into capsules. Preferred dosage forms are prepared by compression eg tablets (including tablets for oral administration, effervescent tablets and tablets adapted to be dispersed in a liquid prior to ingestion), suppositories or inserts and buccal or sub-lingual tablets. In the compression process the tablets are generally formed by a wet granulation, a dry granulation or a direct compression process. In these processes the ingredients are combined as desired, either to form a homogeneous blend which is then compressed into a tablet or to make different blends which are then compressed to make different layers in a tablet. In the wet granulation process, one or both of the active ingredients is homogeneously blended with at least a portion of the carrier and formed into granules by the addition of a granulating fluid preferably in the presence of a granulating agent. Preferably both the ibuprofen medicament and the domperidone medicament are included in the granular product. The granulating agent may be added to (preferably dissolved in) the granulating fluid prior to addition to the blend of active ingredient and carrier or the granulating agent may be blended with the active ingredient and carrier prior to the addition of the granulating fluid. The granulating fluid may be water or an organic solvent, eg a C_{1-6} alkanol such as ethanol, propan-1-ol or propan-2-ol or a mixture thereof. The granulated material is then dried, sieved, added to other ingredients as necessary and blended to form a homogeneous mixture prior to compression into tablets. In the dry granulation process, the ingredients are formed into granules in the absence of a

liquid, such as by roller compaction or slugging. The granules are then mixed with the remaining ingredients and compressed into a solid dosage form. The compositions according to the present invention may also be formed by sieving powdered ingredients into a container and then blending to form a homogeneous mixture. The mixture may be directly compressed into tablets. The "direct compression" process does not include a pre-granulation step. The ingredients are combined to form a homogeneous mixture and then fed to a tabletting for compression into tablets.

In a preferred process, the composition is formed by a process including a wet granulation stage as described above. Desirably, both the active ingredients are present in the granular product together with an inert diluent and a disintegrating agent. In a composition prepared by a more preferred process, a granulating agent or binder is present and comprises a cellulose material (more preferably hydroxypropylmethylcellulose). Preferably, the granulating fluid is water. In a further preferred process, the granulating agent or binder is admixed with the powdered excipients and the granulating fluid (preferably water) added thereto. Preferably the granular product is combined with a lubricant and compressed into tablets.

Thus, in a further aspect, the present invention provides a process to prepare a compressed composition comprising (a) granulating said ibuprofen medicament, optionally with said domperidone medicament, with at least a first portion of said carrier material and a granulating fluid; (b) drying said granules; (c) blending with a lubricating agent and optionally a flow aid to form a homogeneous mixture, and (d) compressing into tablets. In such a process, a cellulose material is the preferred granulating agent.

The dosage forms of the present invention may, if desired, include other compatible pharmacologically active ingredients, eg codeine, caffeine or vitamin products.

The ibuprofen/domperidone combination drug treatment is

primarily intended for the treatment of migraine and other diseases for which the properties of ibuprofen (especially anti-inflammatory, analgesic and anti-pyretic properties) in combination with the properties of domperidone (especially to treat nausea and dyspepsia) are useful.

In accordance with the present invention there is also provided the use of a carrier material which is substantially free of povidone and which comprises at least one diluent combined with at least one release modifying agent in a stable pharmaceutical composition comprising an ibuprofen medicament and a domperidone medicament. Preferably the release modifying agent is a disintegrating agent.

Further general information concerning the excipients may be obtained from The Handbook of Pharmaceutical Excipients (2nd Edition: Ed Wade and Weller) and Remington: Science and Practice of Pharmacy (19th Ed: Ed Gennaro).

The invention will now be illustrated by the following Examples which are given by way of example only. In these examples the ingredients are obtained from the sources listed below:-

Both microcrystalline cellulose and colloidal cellulose are available under the trade names Avicel and are available from FMC Corporation; Croscarmellose sodium is available from FMC Corporation under the trade name Ac-Di-Sol; Hydrogenated cotton seed oil is available from Edward Mendell under the trade name Lubritab; Hydroxypropyl methylcellulose is available from the Dow Corporation under the trade name Methocel E 50; Hydroxypropyl cellulose is available from the Dow Corporation under the trade name Klucel LF; Colloidal silicon dioxide is available from Degussa under the tradename Aerosil; Xanthan gum is available from Monsanto under the trade name Keltrol; Polysorbate 80 is a polyoxyethylene 20 oleate; Polysorbate 60 is polyoxyethylene 20 stearate.

Examples 1 to 3

Ingredient	Example 1	Example 2	Example 3
Ibuprofen	60.5%	60.5%	60.3%
Domperidone Maleate	1.9%	1.9%	1.9%
Microcrystalline cellulose	6.1%	6.1%	-
Croscarmellose sodium	9.7%	9.7%	3.0%
Magnesium stearate	0.6%	-	0.6%
Hydrogenated cotton seed oil	-	0.6%	-
Tricalcium phosphate	18.2%	18.2%	-
Hydroxypropyl cellulose	3.0%	-	-
Hydroxypropylmethyl cellulose	-	3.0%	-
Sorbitol	-	-	34.2%

The composition of Example 1 was prepared according to the following steps:-

(a) the ibuprofen, domperidone maleate, tricalcium phosphate, hydroxypropyl cellulose, croscarmellose sodium and microcrystalline cellulose were sieved and blended to form a homogeneous mixture;

(b) the mixture was granulated to a suitable end point with water and dried;

(c) the dried granules were blended with magnesium stearate;

(d) the lubricated granules were compressed to form tablet cores each containing 200mg of ibuprofen and 5 mg of domperidone or each containing 400mg of ibuprofen and 10 mg of domperidone;

(e) the tablet cores were coated with a conventional film coating.

Example 2 was prepared in a similar manner as described in Example 1 except that hydroxypropylmethyl cellulose replaced hydroxypropyl cellulose in stage (a) as the granulating agent and

hydrogenated cotton seed oil replaced magnesium stearate in stage (c) as the lubricating agent.

Example 3 was prepared in a similar manner as described in Example 1 except that sorbitol replaced the microcrystalline cellulose and tricalcium phosphate and no granulating agent was present in stage (a).

Examples 4 to 6

Ingredient	Example 4	Example 5	Example 6
Ibuprofen	60.5%	62.4%	60.5%
Domperidone maleate	1.9%	2.0%	1.9%
Microcrystalline cellulose	6.1%	6.3%	6.1%
Croscarmellose sodium	9.7%	10.0%	9.7%
Stearic acid	0.6%	0.6%	-
Magnesium stearate	-	-	0.6%
Tricalcium phosphate	18.2%	18.7%	18.2%
Hydroxypropylmethyl cellulose	3.0%	-	3.0%

The tablet cores contained 200 mg or 400 mg ibuprofen.

Example 4 was prepared in a similar manner as described in Example 1 except that hydroxypropylmethyl cellulose replaced hydroxypropyl cellulose in stage (a) as the granulating agent and stearic acid replaced magnesium stearate as lubricant in stage (c).

Example 5 was prepared in a similar manner as described in Example 1 except that no granulating agent was present in stage (a), isopropanol was used as the granulating fluid in stage (b) and stearic acid replaced magnesium stearate as lubricant in stage (c).

Example 6 was prepared in a similar manner as described in Example 1 except that hydroxypropylmethyl cellulose replaced hydroxypropyl cellulose in stage (a) as granulating agent.

Example 7

Ingredient	% w/w
ibuprofen	59.8%
Domperidone	1.9%
Colloidal silicon dioxide	0.2%
Magnesium stearate	0.6%
Lactose	9.2%
Microcrystalline cellulose	22.2%
Sodium lauryl sulphate	1.9%
Sodium starch glycolate	3.5%

The composition of Example 7 was prepared by sieving and blending all the above powdered ingredients to form a homogeneous mixture and compressing to form tablet cores containing 200mg of ibuprofen and 5 mg equivalent of domperidone or each containing 400mg of ibuprofen and 10 mg equivalent of domperidone.

There may also be prepared tablets comprising 200 mg ibuprofen and 10 mg equivalent of domperidone or 400 mg ibuprofen and 20 mg equivalent of domperidone prepared as described in any one of Examples 1-7. The racemic ibuprofen in the above Examples may be replaced by a therapeutically equivalent weight of S(+)-ibuprofen or the sodium or lysine salts of racemic ibuprofen or S(+)-ibuprofen.

Examples 8-35

The following compositions (Examples 8-35) were formed and tested as described below to determine their stability. The ingredients for each Example are set out in Tables 1, 2 and 3.

Examples 8-31 were formed by combining the powder ingredients to form a homogeneous powder blend.

Examples 32-35 were formed by combining the powder ingredients to form a homogenous powder blend and then compressed into tablets.

The Examples were analysed for degradation of the domperidone after storage of the Example compositions for one week under controlled conditions at 50-60°C for detectable levels of the impurity cis-5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]piperidin-4-yl]-2,3-dihydro-1H-benzimidazol-2-one-1-oxide (referred to herein as Domperidone N-oxide). This was measured by HPLC analysis. Examples for which no detectable amount of Domperidone-N-oxide was found (<0.1%) were considered satisfactory.

Table 1

Example	Amount of ingredient (mg)					
	8	9	10	11	12	13
Ibuprofen	200.0	200.0	200.0	200.0	200.0	200.0
Domperidone	2.5	2.5	2.5	2.5	2.5	2.5
Microcrystalline cellulose	100.0	100.0	100.0	100.0	100.0	100.0
Hydroxypropyl methyl cellulose	-	10.0	-	-	-	-
Sodium lauryl sulphate	-	-	10.0	-	-	-
Talc	-	-	-	10.0	-	-
Magnesium stearate	-	-	-	-	10.0	-
Stearic acid	-	-	-	-	-	10.0

Table 1 (cont'd)

Example	Amount of ingredient (mg)			
	14	15	16	17
Ibuprofen	200.0	200.0	200.0	200.0
Domperidone	2.5	2.5	2.5	2.5
Microcrystalline cellulose	100.0	100.0	100.0	100.0
Hydroxypropyl methyl cellulose	10.0	-	-	-
Sodium starch glycolate	-	10.0	-	-
Hydroxypropyl cellulose	-	-	10.0	-
Hydrogenated vegetable oil	-	-	-	10.0

Table 2

Example	Amount of ingredient (mg)					
	18	19	20	21	22	23
Ibuprofen	200.0	200.0	200.0	200.0	200.0	200.0
Domperidone	2.5	2.5	2.5	2.5	2.5	2.5
Lactose	100.0	100.0	100.0	100.0	100.0	100.0
Hydroxypropyl methyl cellulose	-	10.0	-	-	-	-
Sodium lauryl sulphate	-	-	10.0	-	-	-
Talc	-	-	-	10.0	-	-
Magnesium stearate	-	-	-	-	10.0	-
Stearic acid	-	-	-	-	-	10.0

Table 2 (cont'd)

Example	Amount of ingredient (mg)							
	24	15	26	27	28	29	30	31
Ibuprofen	200.0	200.0	200.0	200.0	200.0	200.0	200.0	200.0
Domperidone	2.5	2.5	2.5	2.5	2.5	2.5	2.5	2.5
Colloidal silicon dioxide	100.0	-	-	-	-	-	-	-
Tricalcium phosphate	-	100.0	-	-	-	-	-	-
Maize starch	-	-	100.0	-	-	-	-	-
Pulverised sugar	-	-	-	100.0	-	-	-	-
Sorbitol	-	-	-	-	100.0	-	-	-
Calcium carboxymethyl-cellulose	-	-	-	-	-	100.0	-	-
Dicalcium phosphate	-	-	-	-	-	-	100.0	
Maltodextrin	-	-	-	-	-	-		100.0

Table 3

Example	Amount of ingredient (mg)			
	32	33	34	35
Ibuprofen	200.0	200.0	200.0	200.0
Domperidone	2.5	2.5	2.5	2.5
Microcrystalline cellulose	100.0	100.0	-	-
Lactose	-	-	100.0	100.0
Magnesium stearate	10.0	-	10.0	-
Stearic acid	-	10.0	-	10.0

The analysis of Examples 8-35 found no detectable level of Domperidone N-oxide as an impurity (ie <0.1% by weight).

To the ingredients of Examples 8-31 there may be added a disintegrant (eg croscarmellose sodium), a flow aid (eg colloidal silicon dioxide) and also a lubricant (eg magnesium stearate) (as described herein) followed by compression into tablets.

Example 36

Ingredient	% w/w
Ibuprofen	59.9 (200 mg)
Domperidone	0.6
Microcrystalline cellulose	18.0
Lactose	12.0
Magnesium stearate	0.5
Starch	9.0

A tablet formulation containing the ingredients listed above was prepared in a similar manner to that described in Example 3 or by direct compression in a similar manner to that described in Example 7.

The following Example formulations may also be prepared:

Example 37: Sustained Release Tablet

Ingredient	% w/w
Domperidone maleate	3.7
Ibuprofen	74.1
Xanthan gum	18.5
Hydroxypropyl methylcellulose	2.2
Stearic acid	1.1
Colloidal silicon dioxide	0.4

A sustained release tablet may be prepared by granulating the hydroxypropyl methylcellulose and ibuprofen with approximately 20% of the total content of xanthan gum using water as the granulating agent. The ibuprofen granule is combined with the remainder of the xanthan gum and the other ingredients and compressed into tablets containing 400 mg ibuprofen and 20 mg domperidone.

Example 38: Capsule

Ingredient	% w/w
Ibuprofen	60.6
Domperidone	3.0
Lactose	30.3
Croscarmellose sodium	6.1

The ingredients were formed into a homogeneous blend and filled into a conventional hard gelatin capsule containing 200 mg ibuprofen and 10 mg domperidone.

Example 39: Liquid Susp nsion

Ingredient		% w/w
Domperidone maleate		0.2
Ibuprofen		2.0
Colloidal cellulose		2.5
Glycerin		15.0
Sorbitol		10.0
Kaolin		1.0
Polysorbate 80		0.1
Purified water BP	to	100

The polysorbate 80 may be added to the water followed by the addition of glycerin with stirring. The domperidone and ibuprofen may then be added and also the colloidal cellulose, sorbitol and kaolin (as thickeners) with continued stirring until a satisfactory suspension is formed.

Example 40: Effervescent Granules

Ingredient	% w/w
Domperidone maleate	0.3
Ibuprofen	10.2
Microcrystalline cellulose	2.5
Pulverised sugar	51.2
Malic acid	25.5
Sodium bicarbonate	7.7
Anhydrous sodium carbonate	2.6
Sodium lauryl sulphate	0.1

The domperidone, ibuprofen, microcrystalline cellulose and sugar are granulated with water and then thoroughly dried. The remaining

ingredients are added to form a powder mixture and filled into sachets each containing 400 mg ibuprofen and 20 mg domperidone maleate.

Example 41: Chewable Tablet

Ingredient	% w/w
Ibuprofen	17.6
Domperidone maleate	0.6
Sucrose	66.0
Sorbitol	13.2
Fumed silica	0.8
Stearic acid	1.8

The above ingredients are combined to form a homogeneous blend followed by direct compression to form a chewable tablet containing 200 mg ibuprofen and 7.5 mg domperidone maleate.

Example 42: Suppository

Ingredient	% w/w
Domperidone maleate	0.9
Ibuprofen	23.6
Polysorbate 60	4.7
Witepsol H185	70.8

The polysorbate is dispersed in the molten Witepsol followed by the addition of the ibuprofen and domperidone. The mixture is then injected into moulds to produce a suppository shape and cooled to ambient temperature. The suppository contains 600 mg ibuprofen and 22.5 mg domperidone maleate.

Comparative Exampl 1

Ibuprofen (200 mg) and domperidone maleate (2.5 mg) were formed into a granule by a standard granulating process using water and isopropyl alcohol as the granulating fluid. After storage for one week at 50-60°C no detectable level of Domperidone-N-oxide as impurity (as described in the test described above) was found (ie <0.1%). When povidone (10 mg) was additionally incorporated into the granule an impurity level of greater than 1.5% (as defined above) was found after storage for one week at 50-60°C.

Comparative Example 2

Ibuprofen was combined with domperidone maleate on a conventional mixer to produce a homogenous powder blend containing 200 mg ibuprofen and 2.5 mg domperidone maleate. The product was stored for one week at 50-60°C. On analysing the product after storage, no detectable level of impurity (as defined above) was found to be present.

In contrast, when povidone (20 mg) was incorporated into the powder blend, the level of impurity after storage for one week at 50-60°C was found to be about of 0.7% by weight. When crospovidone (Kollidon CL) was incorporated into the tablet in replacement for the povidone, the level of impurity (as defined above) after storage for one week at 50-60°C was found to be about 7.9% by weight.

Comparative Examples 3 and 4

In a similar way to that described in Example 2, povidone (10 mg) was incorporated into the powder blend of Example 8 (comparative Example 3) and also in the powder blend of Example 19 (comparative Example 4), after storage for one week at 50-60°C, the level of impurity (as defined above) was found to be approximately 0.5% by weight. The results with

and without povidone (pvp) are given in Table 4 below.

Table 4

Comparative Example	% Impurity (1 week) without pvp	% Impurity (1 week) with pvp
3	<0.1%	~0.5%
4	<0.1%	~0.5%

5

CLAIMS

1. A stable pharmaceutical composition comprising a mixture of
   (i) an ibuprofen medicament;
   (ii) a domperidone medicament; and
   (iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent.

2. A stable pharmaceutical composition comprising a mixture of
   (i) an ibuprofen medicament;
   (ii) a domperidone medicament; and
   (iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent, excluding

(a) a compressed tablet comprising granulated ibuprofen and a carrier material consisting essentially of either maize starch at 35-38% total tablet weight in combination with dried maize starch at 3-4% total tablet weight or microcrystalline cellulose at 10-11% total tablet weight in combination with croscarmellose sodium at 14-16% total tablet weight and pre-gelled starch at 10% total tablet weight;

(b) a direct compression tablet comprising a carrier material consisting essentially of microcrystalline cellulose at 8-11% total tablet weight and lactose at 5-6% total tablet weight;

(c) a hard gelatin capsule comprising a carrier consisting essentially of maize starch at 15-20% total capsule contents weight in combination with pre-gelled starch at 5-6% total capsule contents weight.

3. A compressed tablet composition including an ibuprofen medicament, a domperidone medicament and a carrier material comprising a compressed mixture of

(a) a granular component comprising said ibuprofen medicament and at least a first portion of said carrier material; and

(b) a powder component comprising a lubricant material and an optional further portion of said carrier material,

said domperidone medicament being present in either of components (a) and (b), characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one disintegrating agent.

4. A composition according to any one of claims 1 to 3 characterised by comprising a granulating agent present to an extent of up to 10% of total tablet weight.

5. A composition according to any one of claims 1 to 4 comprising a granulating agent consisting essentially of one or more of the following:

polymeric granulating agents selected from natural gums, synthetic gums and cellulose materials; a sugar granulating agent; a starch granulating agent.

6. A composition according to either one of claims 4 and 5 characterised in that the granulating agent is a cellulose derivative.

7. A tablet according to claim 6 characterised in that the granulating agent is hydroxypropyl cellulose or hydroxypropyl methylcellulose.

8. A directly compressed tablet composition comprising

(i) an ibuprofen medicament;
(ii) a domperidone medicament; and

(iii) a carrier material,

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one disintegrating agent and a lubricating agent.

9. .A composition according to any one of the preceding claims comprising 20-60% carrier material including up to 15% of a discrete disintegrant material.

10. A composition according to any one of the preceding claims wherein the carrier material consists essentially of a diluent substantially without disintegrating properties, a diluent with disintegrating properties, a discrete disintegrant and a lubricating agent.

11. A composition according to any one of the preceding claims wherein the carrier material comprises a cellulose component, a phosphate component, a starch component or a sugar component or mixtures thereof.

12. A composition according to any one of the preceding claims wherein the carrier material consists essentially of one or more of the following diluents: microcrystalline cellulose, tricalcium phosphate and lactose.

13. A composition according to any one of the preceding claims comprising one or more discrete disintegrants including croscarmellose sodium and sodium starch glycolate.

14. A composition according to any one of the preceding claims in the form of a unit dose comprising 50-400 mg ibuprofen medicament and 5-20 mg domperidone medicament.

15. A solid composition comprising a non-compressed mixture of

(i) an ibuprofen medicament;
(ii) a domperidone medicament; and

(iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent.

16. A liquid or semi-solid composition comprising

(i) an ibuprofen medicament;
(ii) a domperidone medicament; and
(iii) a carrier material

characterised in that the carrier material is substantially free of povidone and comprises at least one diluent combined with at least one release modifying agent.

17. A composition according to any one of the preceding claims comprising either racemic ibuprofen or S(+)-ibuprofen or the sodium or lysine salts thereof, present to an extent of 50-65% by weight of the composition.

18. A composition according to any one of the preceding claims comprising either domperidone or the maleate salt thereof, present to an extent of 1-5% of the composition.

19. The use of a carrier material which is substantially free of povidone and which comprises at least one diluent combined with at least one release modifying agent in a stable pharmaceutical composition comprising an ibuprofen medicament and a domperidone medicament.

20. The use according to claim 19 wherein the release modifying agent is a disintegrating agent.

21. A process to prepare a pharmaceutical composition according to claim 1 comprising incorporating said ibuprofen medicament and said domperidone medicament with the carrier material as a homogeneous

blend and forming it into a unit dosage form.

22. A process to prepare a compressed composition according to any one of claims 1-6 comprising (a) granulating said ibuprofen medicament, optionally with said domperidone medicament, with at least a first portion of said carrier material and a granulating fluid; (b) drying said granules; (c) blending with a lubricating agent and optionally a flow aid to form a homogeneous mixture, and (d) compressing into tablets.

23. A process according to claim 22 further comprising a cellulose material as a granulating agent.

24. A method of treating migraine which comprises the administration to a patient in need thereof a stable pharmaceutical composition according to any one of claims 1-18.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/EP 99/05753

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A61K9/20 A61K31/445 //(A61K31/445,31:19)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	CA 2 020 018 A (SIMMONS DON L) 28 December 1991 (1991-12-28) cited in the application claims 1-3,7,8; examples ---	1-5, 8-13,15, 17-21,24
X	GB 2 313 309 A (ON NINH) 26 November 1997 (1997-11-26) cited in the application page 4, line 13 - line 36; claims ---	1-3,5,6, 8,10-12, 15,16, 19-21,24
P,X	WO 98 34612 A (PANKHANIA MAHENDRA GOVIND ;BOOTS CO PLC (GB); YURDAKUL SARUHAN (GB) 13 August 1998 (1998-08-13) cited in the application page 2, line 14 -page 7, line 11 claim 1; examples 6-11,15,16 -----	1-24

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

° Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
20 January 2000	27/01/2000

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Epskamp, S

3

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/EP 99/05753

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. [X] Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Remark: Although claim 24 is directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the composition.

2. [ ] Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. [ ] Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. [ ] As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. [ ] As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. [ ] As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. [ ] No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

[ ] The additional search fees were accompanied by the applicant's protest.

[ ] No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No
PCT/EP 99/05753

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
CA 2020018 A	28-12-1991	US 5273759 A	28-12-1993
GB 2313309 A	26-11-1997	NONE	
WO 9834612 A	13-08-1998	AU 6295598 A	26-08-1998
		CZ 9902709 A	13-10-1999
		GB 2331926 A	09-06-1999
		NO 993784 A	22-09-1999
		ZA 9800968 A	06-08-1998